Low- and middle-income countries (LMICs) carry 80% of the global disease burden. They represent less than 10% of clinical trial enrollment. This mismatch isn't incidental — it's structural. And it's starting to change.
Of the approximately 490,000 trials registered on ClinicalTrials.gov, roughly 70% are conducted primarily in high-income countries — the United States, Western Europe, Japan, Australia. Sub-Saharan Africa, home to 1.2 billion people and enormous infectious and non-communicable disease burden, accounts for roughly 3% of global trial enrollment. South Asia, with 2 billion people, is similarly underrepresented despite being a major trial destination for some pharmaceutical sponsors.
This creates a compounding inequality: the treatments that get developed are optimized for populations that participated in the trials. Drug dosing, efficacy endpoints, and safety profiles are validated on predominantly Western, white, male cohorts — and then applied globally to populations that weren't represented.
The primary scientific and regulatory language of clinical research is English. Consent forms, eligibility criteria, study protocols, and investigator training are all predominantly in English. A patient in rural Tamil Nadu or Lagos — even one who speaks multiple local languages — may be effectively excluded from trials by language alone.
Phase 2 and Phase 3 trials require consistent access to certified research sites with specialized equipment, trained coordinators, and cold-chain storage for investigational drugs. These sites are concentrated in urban centers, and the rural populations with the highest disease burden are often hours away.
In high-income countries, patients with serious conditions are often referred to trials by their oncologists or specialists. This referral pipeline barely exists in LMICs — primary care physicians who are the sole healthcare contact for millions of patients rarely have time or resources to identify relevant trials for their patients.
Sponsors face significant overhead in regulatory submissions to CDSCO (India), NAFDAC (Nigeria), SAHPRA (South Africa), and other national bodies — on top of FDA or EMA requirements. Many sponsors simply don't run global trials to avoid this complexity, even when the science would benefit from diverse populations.
Participation in a trial often requires multiple visits to a research site, which requires transportation, time off work, and childcare. Stipends for participants are regulated and often don't fully cover these costs. For daily-wage workers in LMICs, participation is economically irrational even when medically attractive.
The underrepresentation of LMIC populations in trials isn't just an equity problem — it's a science problem:
COVID-19 forced rapid adoption of decentralized trial components — remote visits, local labs, direct-to-patient drug delivery. These innovations are being retained and expanded. For LMIC populations, DCT elements reduce the geographic access barrier significantly.
In many LMICs, mobile phone penetration exceeds 90% while computer penetration remains low. Pharmaceutical sponsors are beginning to invest in SMS-based and app-based screening tools that meet patients where they are, on the device they already have.
Programs that train community health workers to identify potentially eligible patients and facilitate trial referral have shown significant enrollment improvements in Africa and South Asia. This leverages existing trusted relationships in communities where physician contact is infrequent.
The International Council for Harmonisation (ICH) is making slow but real progress on global regulatory harmonization. The African Medicines Agency (AMA), established in 2021, aims to create a single regulatory pathway across AU member states — potentially transforming the economics of African trial conduct.
Offline-capable translation and information tools can now operate on a $50 Android phone. The same ML models that run on-device in San Francisco can run in a village in Zambia — if someone builds the application. This is one of the few structural barriers that technology can directly address without waiting for regulatory or infrastructure change.
Offline-first clinical trial finder with on-device translation into 10 languages — including Hindi, Swahili, Indonesian, Arabic, and Bengali. Free for patients. Designed for the populations most underserved by existing tools.
Learn About HealthBridge →For informational purposes only. Statistics sourced from ClinicalTrials.gov, WHO, and published literature. Not medical advice.